Clinical Operations in Oncology Trials East Coast 2017
Clinical Operations in Oncology Trials (CTO) is the only operationally-focused oncology conference in the USA. Alongside our West Coast conference, the East Coast conference in the Boston biotech hub is tailored specifically for Clinical Operations/Development/Research and Medical Affairs pharma and biotech representatives in the region. With a dynamic programme written for the industry, by the industry, our 7th annual CTO East Coast event and promises to be an engaging and memorable conference. Optimizing clinical processes within oncology trials to ensure effective patient recruitment, trial management and achieve trial success is central to this year’s conference.
- Howard Fingert, Senior Medical Director, Takeda covers the ongoing developments within the Binden Moonshot programme and current regulatory developments within clinical trials
- Richard Woodman, SVP, US Oncology Clinical Development & Medical Affairs, Novartis will explore aligning clinical trials with the correct placement and engaging sites for optimisation for maximum trial outcome
- Hear directly from a patients perspective as Jack Whelan, Cancer Survivor illustrates the shortcomings and opportunities to improve Clinical Trials and research and care within clinical trials
- Join our interactive discussion featuring a patient panel hosted by Michael Katz, Medical Director-Radiation Oncology, Lowell General Hospital to uncover the outlining what factors are involved in their recruitment and engagement with a trial and designing patient centric focus to trial design
What does a Trump presidency mean for oncology research?
On the 20th January, Trump assumed office of the United States of America. 2 months following the election results, high levels of uncertainty still spread across not only the United States but the whole world. What plans did Trump have? Why did he not mention research funding during his campaign? What did Trump’s immigration law changes have in store? Various questions were left floating around the clinical trial industry. In 2016, it was estimated that approximately 1,685,210 new cases of cancer would be diagnosed, resulting in more than half a million deaths within the States. It was in 1971 that the then U.S. President Richard Nixon signed the National Cancer Act – a major point in our history and our fight against one of the leading causes on premature death. Over the past years, we have seen a massive incline in cancer deaths yet as a global community, we strive to fight back. Will Trump stand in the way of this?
Promote your attendance at Oncology East 2017
Are you registered to attend the 7th annual Clinical Operations in Oncology Trials 2017? Promote your attendance to this year’s event with one of our banners below! If you require additional banners,
Melanie Clement - Marketing Executive
Who should attend this event?
CEO, COO, CSO, CMO, Clinical Operations, Clinical Research / Clinical Trials, Clinical Oncology, Medical Affairs / Medical Research, Clinical Coordinator, Clinical Project Manager, Clinical Program Manager, Clinical Development, Oncology R&D, Oncology Discovery / Development, Regulatory Affairs, Clinical Knowledge/ Competitive Intelligence
FIND MORE CONFERENCES AT PHARMATUTOR